Joseph S. Dillon, Ph.D., MBA, is Chief Executive Officer and Member of BioPact bringing over two decades of medical industry experience to the BioPact team. Joe joined BioPact in July 2015 as a consultant to lead its business development efforts with medical industry companies. Joe became BioPact’s CEO in November 2015, taking responsibility for all the firm’s activities. Joe is a seasoned executive with 25+ years’ experience in global pharmaceutical and biotechnology business strategy and planning, product development, operations, business development and strategic transactions. He has been instrumental as a senior executive in the building of four companies; closing over 40 transactions including licensing, M&A, and financing (including an IPO); and hundreds of product/technology assessments. Most recently, Joe was President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, a strategy and business analytics advisory firm, providing strategic, business development and transactional support for pharma and biotech companies, large and small, globally. Prior to that, Joe held senior positions in pharmaceutical management consulting firms, most significantly was as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health), where Joe built the practice and led numerous projects including licensing and M&A transactions, deal/technology valuations, and corporate strategy. Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer, which Joe lead to high growth, operating profitability, and a lucrative divestiture for investors; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company, where Joe lead their successful IPO process; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer, where Joe was instrumental in growing revenue from $4M to $80M and hitting profitability in less than two years; and corporate positions with predecessor companies of Sanofi, a major global pharmaceutical company. Joe is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He holds a Ph.D. in Metaphysics, M.B.A. in International Finance and a bachelors in Finance.
Lainie Mulvanny is the Vice President of Business Development at BioPact. She is focused on corporate and academic collaborations to develop MGMR® enabled products for medical use. She is responsible for the assessment of unmet needs in the drug delivery space and the development of strategies for BioPact’s partnering-focused development model. Prior to joining BioPact, Lainie was a Clinical Science Specialist at Sanofi Genzyme responsible for market assessment, customer support and sales forecasting. Prior to that, Lainie held positions of increasing responsibility ending as Disease Focused Specialty Representative at Merck. Her responsibilities at Merck involved detailing prescription drugs for cardiovascular, metabolism and respiratory disease, as well as vaccines to doctors in Arizona. Prior to that, she held sales representative positions at Zila Pharmaceuticals and Ciba Vision. Lainie earned a BA in Behavioral Sciences at California State Polytechnic University – Pomona.
Paul Everill, Ph.D. is the Director of Research and Development at BioPact. Paul is an employee of Molecular Rebar Design, a parent company of BioPact, and is on contract to BioPact for 100% of his time. Paul has a BS in Biochemistry and a BA in English from the University of Texas – Austin. He attended Tufts University-Sackler School of Biomedical Sciences to earn his doctorate in Mechanistic Enzymology. In Paul’s first post-doctoral appointment at Arisaph Pharmaceuticals he designed a mass spectrometry-based assay for detecting peptide degradation products in mouse serum. This led to the furthering of the theory on controlling diabetes with peptides instead of insulin; his work was included in a paper published in Diabetes (2015). During his second post-doctoral project at Boston University, Paul was instrumental in developing the theory of action for a new series of inhibitors for Prion protein aggregation. Paul joined Molecular Rebar Design in 2013 to support the development of the proprietary carbon nanotube technology, MOLECULAR REBAR® (MR). He reformulated MR for use in material applications and developed the base dispersion process that directly led to the launch of the company’s first marketed products. Paul served as Director of the Lead Acid Battery division; the company’s largest team of scientific professionals.
Aaron Tasset is a Research and Development Scientist for BioPact. Aaron joined BioPact in 2015 as part of its founding scientific team. Since that time, Aaron has designed, led, and performed many significant studies that have built a robust data set for the formulation and application of MGMR in various medical uses. Aaron received his degree in biomedical engineering from the University of Miami, with specialization in cellular and tissue engineering. During his undergraduate work, he developed excellent laboratory techniques and knowledge that allow him to meaningfully contribute to the generation of necessary data to position MGMR® as an invaluable biotechnology in the pharmaceutical industry. Aaron is passionate about being at the forefront of a groundbreaking technology that has the potential to positively impact the lives of so many people.
BioPact Ventures, LLC Member Group
In addition to Dr. Dillon, the following are members of the LLC:
Kurt Swogger, PE is a Managing Member, Inventor and Co-founder of BioPact. Kurt is CEO and founder of Molecular Rebar Design, which through MRMedical LLC, owns the majority of BioPact’s LLC units. Given MRMedical’s majority share, Kurt’s role as LLC Managing Member is comparable to Chairman of the Board. Kurt is co-inventor of MOLECULAR REBAR and holds many patents. Kurt began his career at The Dow Chemical Company in 1972. While there, he held positions in research, manufacturing, and marketing in the Ag Chemicals, Consumer Products, and Polyolefins businesses. In 2003, he was appointed Vice President of R&D and was responsible for polystyrene, automotive, engineering plastics, building and construction products, rubber, and thermosets. In 2005, he was named R&D Vice President for the Performance Plastics and Chemicals Businesses. He also served on the board of directors for Univation, a joint venture between Dow and Exxon. He retired from Dow in 2007. Kurt received his BS in Chemical Engineering from Case Western Reserve University and is a Registered Professional Engineer in Texas. Swogger has been honored with many distinguished awards. He received the US Medal of Technology, the Corporate Innovators Award, the American Chemical Society’s Chemical Leadership Award, and the AIChE Product Innovations Award. In addition to his leadership role at MRD, Kurt is also the Executive VP of Investments and a board member of Planned Innovation Institute and an active member in the Plastics Pioneers Association. To share his entrepreneurial expertise, Kurt serves on the board of several start-up companies, including Liquid Light, Wildcat Technologies, and Rennovia.
Randy Kinsel is a Managing Member and Co-founder of BioPact. Randy, through his majority stake in IPRD LLC, owns a minority stake in BioPact. Randy co-founded BioPact after successful entrepreneurial endeavors in multiple industries. Randy was instrumental in securing BioPact's exclusive license from MRD to commercialize MGMR® in the global medical market. Prior to bringing in Dr. Dillon as CEO in 2015, Randy, as Co-CEO, coordinated BioPact's scientific, IP, and business development efforts in the medical field with the inventors' commercialization efforts in non-medical applications. He knows what it takes to drive a start-up to success, and plays an influential role in the development of BioPact’s business strategy.
Clive Bosnyak, Ph.D. is a Member, Inventor and Co-founder of BioPact. Clive is a Member of MRMedical LLC, along with Kurt Swogger. Clive is Chief Scientific Officer and co-founder of Molecular Rebar Design. Clive is also co-inventor of MOLECULAR REBAR and holds many patents. He is an active and valued scientific advisor on many BioPact initiatives. Clive is also founder of several other technology companies formed since 2006. Prior to co-founding MRD, Clive had a long and successful career at Dow Chemical Company. Clive is an award winning scientist, including “Inventor of the Year” from Houston IP Law Assoc. for the invention of MOLECULAR REBAR, and a recognized expert in industrial sciences, including nanotechnology, polymers, and energy. He earned his Ph.D. in Chemistry from the University of Birmingham in the United Kingdom.
Kent Phelps is a Member and Co-founder of BioPact. Kent is a Member of IPRD LLC, along with Randy Kinsel. Kent was Co-CEO of BioPact prior to binging in Dr. Dillon as CEO in 2015 and accomplished the following: successfully negotiated the initial license and supply agreement with the inventors of the breakthrough carbon nanotube technology (Medical Grade MOLECULAR REBAR®); created and implemented the 5 year business plan; raised the seed funding; recruited the initial management and scientific team; built the BioPact/MGMR® brand; fostered relationships with insiders and KOL’s in the biopharmaceutical industry; established the concept of BioPact’s nano-technology as a potential targeted drug delivery technology; established ongoing meaningful dialogue with potential Big Pharma partners; and recruited his replacement - long-time industry insider Joseph S. Dillon, who now serves as CEO of BioPact. Kent continues to be involved with BioPact and serves as Chief Legal Counsel.